4D Molecular Therapeutics (FDMT) Return on Sales (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Return on Sales data on file, last reported at 0.31% in Q1 2026.

• On a quarterly basis, Return on Sales rose 3500.0% year-over-year to 0.31% in Q1 2026; TTM through Mar 2026 was 0.03%, a 9710.0% increase from a year earlier, with the FY2025 full-year figure at 0.04%, up 7804.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.31%, down from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for FDMT reached as high as 17.41% in Q4 2023 and fell as low as 505.5% in Q4 2024.
• Historically, Return on Sales has averaged 56.78% across 5 years, with a median of 2.11% in 2022.
• Across the five-year window, Return on Sales tumbled 52291 bps in 2024 and surged 50550 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.24% in 2022, then soared by 7268 bps to 17.41% in 2023, then slumped by 3004 bps to 505.5% in 2024, then soared by 100 bps to 0.0% in 2025, then slumped by 14809 bps to 0.31% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.31% in Q1 2026, 0.0% in Q4 2025, and 9.54% in Q3 2025.